Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A young women with clinical and histological features of chronic active hepatitis was noted to have extremely high levels of immunoglobulin (14.6 g per dl). This was associated with the hyperviscosity syndrome, diffuse coagulation abnormalities, and renal insufficiency in the absence of severe liver disease. Correction of these features occurred with plasmapheresis before corticosteroid therapy was begun. A similar group of persons with very high gamma-globulin levels, described previously under the heading of "plasma cell hepatitis," may form a distinct and rare subgroup of chronic active hepatitis patients.
 ...
PMID:Hyperviscosity syndrome attributable to hyperglobulinemia in chronic active hepatitis. 7 88

A case is reported of chronic polyarthritis, hepatitis and hyperviscosity syndrome associated with the presence of intermediate and high molecular weight plasma complexes, a mixed cryoprotein and widespread endarteritis obliterans of small muscular arteries. The features of this case are compared with those of other reported cases of connective tissue disease associated with hyperviscosity syndrome.
 ...
PMID:Connective tissue disease and hyperviscosity syndrome with cryoprotein and immune complexes. Report of a case with autopsy findings and review of the literature. 73 92

Carbon tetrachloride-induced hepatitis in rats is accompanied by blood hyperviscosity syndrome development. A course intragastric administration of thiophane under these conditions prevents the increase in whole blood viscosity by normalizing the microrheological indices (deformability and aggregation of erythrocytes), which is manifested by increasing oxygen availability for tissues.
 ...
PMID:[Hemorheological effects of thiophane on tetrachloromethane induced hepatic damage]. 2091 56

Cryoglobulinaemic syndrome (CS) includes clinical signs and symptoms that range from the classic triad of Meltzer and Franklin (purpura, weakness and arthralgias) to multiple organ involvement, and it may be characterised by nociceptive or neuropathic pain. Both types of pain use the same pathways and neurotransmitters, but nociceptive pain has an adaptive system and biological function whereas neuropathic pain does not. Managing CS means dealing with often very different clinical patterns, activity and severity with the aim of preventing irreversible organ damage, reducing pain, improving the patients' quality of life and reducing social costs. However, treatment is still largely empirical, and it is often delayed. The Italian Group for the Study of Cryoglobulinaemia (GISC) strongly recommended a low-antigen-content diet and colchicine for all symptomatic CS patients. Patients with mild-moderate symptoms (such as purpura, weakness, arthralgia and initial neuropathy) have been treated with low or medium doses of steroids, and, in the presence of chronic hepatitis C virus (HCV)-related hepatitis, an attempt has been made to eradicate HCV with pegylated interferon plus ribavirin. In the case of severe or rapidly progressive disease (glomerulonephritis, neuropathy, leg ulcers, widespread vasculitis or hyperviscosity syndrome), more aggressive treatment should be used (e.g., high doses of corticosteroids, plasma exchange plus cyclophosphamide or rituximab). Pain management in CS therefore depends on the type of pain (nociceptive, neuropathic or mixed), the characteristics of the patients and their co-morbidities. Drug therapy should be carefully monitored in order to obtain prompt and beneficial results.
...
PMID:Pain management in cryoglobulinaemic syndrome. 2626 2